TY  - JOUR
AU  - Damjanović, Ana B.
AU  - Matić, Ivana Z.
AU  - Dordić, Marija
AU  - Nikolić-Durović, Marina
AU  - Nikolić, Srdan
AU  - Roki, Ksenija
AU  - Milovanović, Zorka
AU  - Antić-Stanković, Jelena
AU  - Dzodić, Radan
AU  - Damjanović, Svetozar S.
AU  - Kanjer, Ksenija
AU  - Abu Rabi, Zaki
AU  - Juranić, Zorica
PY  - 2015
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2457
AB  - The aim of research was to determine the effects of maximally therapeutically achievable concentrations of metformin on malignant cells and healthy peripheral blood mononuclear cells (PBMC). Eight patients with T2D or hyperglycemia and nine healthy volunteers were included in the study. For determination of the influence of metformin on the phenotype of breast carcinoma, 1,410 patients with surgically removed tumors were included. From this group 37 breast cancer patients had DM type 2 or hyperglycemia and were pretreated with metformin alone or sometimes in combination with other antidiabetic drugs. Our results proved that metformin at low concentrations induced mild decrease in survival of malignant cells and PBMC stimulated for proliferation, but it didn't affect survival of resting PBMC. The effects of plasma of hyperglycemic patients who were under metformin therapy on autologous PBMC-induced decrease in survival of MDA-MB-361 cells, was noticeable in some patients. Metformin pretreatment for 24 h of HER2+ MDA-MB-361 cells, which were subsequently treated for 48 h with Herceptin, induced additional decline in cell survival. The analysis of influence of metformin on phenotype of breast cancer cells revealed significantly lower number of diabetic cancer patients treated with metformin with overexpressed HER2+ tumors (p  lt  0.013), while the number of patients with ER+PR+ tumors was not significantly changed (p  lt  0.832). In conclusion, therapeutically used concentrations of metformin exhibit mild cytotoxic action on malignant and dividing normal cells pointing to its preferred role in malignant and autoimmune diseases. The use of metformin was associated with pronounced decrease in HER2 overexpressing tumors.
PB  - Springer, Dordrecht
T2  - Pathology & Oncology Research
T1  - Metformin Effects on Malignant Cells and Healthy PBMC; The Influence of Metformin on the Phenotype of Breast Cancer Cells
VL  - 21
IS  - 3
SP  - 605
EP  - 612
DO  - 10.1007/s12253-014-9864-9
ER  - 

@article{
author = "Damjanović, Ana B. and Matić, Ivana Z. and Dordić, Marija and Nikolić-Durović, Marina and Nikolić, Srdan and Roki, Ksenija and Milovanović, Zorka and Antić-Stanković, Jelena and Dzodić, Radan and Damjanović, Svetozar S. and Kanjer, Ksenija and Abu Rabi, Zaki and Juranić, Zorica",
year = "2015",
abstract = "The aim of research was to determine the effects of maximally therapeutically achievable concentrations of metformin on malignant cells and healthy peripheral blood mononuclear cells (PBMC). Eight patients with T2D or hyperglycemia and nine healthy volunteers were included in the study. For determination of the influence of metformin on the phenotype of breast carcinoma, 1,410 patients with surgically removed tumors were included. From this group 37 breast cancer patients had DM type 2 or hyperglycemia and were pretreated with metformin alone or sometimes in combination with other antidiabetic drugs. Our results proved that metformin at low concentrations induced mild decrease in survival of malignant cells and PBMC stimulated for proliferation, but it didn't affect survival of resting PBMC. The effects of plasma of hyperglycemic patients who were under metformin therapy on autologous PBMC-induced decrease in survival of MDA-MB-361 cells, was noticeable in some patients. Metformin pretreatment for 24 h of HER2+ MDA-MB-361 cells, which were subsequently treated for 48 h with Herceptin, induced additional decline in cell survival. The analysis of influence of metformin on phenotype of breast cancer cells revealed significantly lower number of diabetic cancer patients treated with metformin with overexpressed HER2+ tumors (p  lt  0.013), while the number of patients with ER+PR+ tumors was not significantly changed (p  lt  0.832). In conclusion, therapeutically used concentrations of metformin exhibit mild cytotoxic action on malignant and dividing normal cells pointing to its preferred role in malignant and autoimmune diseases. The use of metformin was associated with pronounced decrease in HER2 overexpressing tumors.",
publisher = "Springer, Dordrecht",
journal = "Pathology & Oncology Research",
title = "Metformin Effects on Malignant Cells and Healthy PBMC; The Influence of Metformin on the Phenotype of Breast Cancer Cells",
volume = "21",
number = "3",
pages = "605-612",
doi = "10.1007/s12253-014-9864-9"
}

Damjanović, A. B., Matić, I. Z., Dordić, M., Nikolić-Durović, M., Nikolić, S., Roki, K., Milovanović, Z., Antić-Stanković, J., Dzodić, R., Damjanović, S. S., Kanjer, K., Abu Rabi, Z.,& Juranić, Z.. (2015). Metformin Effects on Malignant Cells and Healthy PBMC; The Influence of Metformin on the Phenotype of Breast Cancer Cells. in Pathology & Oncology Research
Springer, Dordrecht., 21(3), 605-612.
https://doi.org/10.1007/s12253-014-9864-9

Damjanović AB, Matić IZ, Dordić M, Nikolić-Durović M, Nikolić S, Roki K, Milovanović Z, Antić-Stanković J, Dzodić R, Damjanović SS, Kanjer K, Abu Rabi Z, Juranić Z. Metformin Effects on Malignant Cells and Healthy PBMC; The Influence of Metformin on the Phenotype of Breast Cancer Cells. in Pathology & Oncology Research. 2015;21(3):605-612.
doi:10.1007/s12253-014-9864-9 .

Damjanović, Ana B., Matić, Ivana Z., Dordić, Marija, Nikolić-Durović, Marina, Nikolić, Srdan, Roki, Ksenija, Milovanović, Zorka, Antić-Stanković, Jelena, Dzodić, Radan, Damjanović, Svetozar S., Kanjer, Ksenija, Abu Rabi, Zaki, Juranić, Zorica, "Metformin Effects on Malignant Cells and Healthy PBMC; The Influence of Metformin on the Phenotype of Breast Cancer Cells" in Pathology & Oncology Research, 21, no. 3 (2015):605-612,
https://doi.org/10.1007/s12253-014-9864-9 . .

TY  - JOUR
AU  - Milicević, Zorka
AU  - Kasapović, Jelena
AU  - Gavrilović, Ljubica
AU  - Milovanović, Zorka
AU  - Bajić, Vladan
AU  - Potparević, Biljana
PY  - 2014
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2096
AB  - It is well recognized that cancers develop and grow as a result of disordered function of tumor suppressor genes and oncogenes, which may be exploited for screening purposes. Extensive evidence indicated tumor suppressor protein p53 as candidate marker for mutation identification. We have investigated mutant p53 protein expression in human breast tumors in relation to antioxidant status deficiency. The study included 100 breast cancer patients. p53 protein expression was evaluated by Western blot assay and immunostaining using a CM-1, DO-7 and Pab240 antibodies. Antioxidant parameters and lipid peroxidation were estimated by biochemical analyses. Western blotting with epitope-specific monoclonal antibody Pab240 strongly suggests that nuclear extracts from breast cancer cells express mutant forms of p53. It is of interest that the mutant forms of p53 overexpression in conjunction with the appearance of nuclear bodies are observed in highly aggressive carcinomas. Expression of isoform Delta p53 (45 kDa) and isoform of similar to 29 kDa were more common in cases with LN metastasis. These studies point out the molecular consequences of oxidative stress (lipid peroxides, LP, p lt 0.001) and antioxidant status deficiency (copper, zinc superoxid dismutase, SOD, p lt 0.001; catalase, CAT, p lt 0.01; glutathione reductase, GR, p lt 0.001; glutathione, GSH, p lt 0.05) and indicate the importance of p53 mutation as the commonest genetic alteration detected in breast cancer cells. The expression of mutant p53 is correlated to increased lipid peroxides (0.346, p lt 0.05) and lowered antioxidant activity of CAT (- 0.437, p lt 0.01) in the breast cancer patients.
PB  - Excli Journal Managing Office, Dortmund
T2  - EXCLI Journal
T1  - Mutant p53 protein expression and antioxidant status deficiency in breast cancer
VL  - 13
SP  - 691
EP  - 708
UR  - https://hdl.handle.net/21.15107/rcub_vinar_113
ER  - 

@article{
author = "Milicević, Zorka and Kasapović, Jelena and Gavrilović, Ljubica and Milovanović, Zorka and Bajić, Vladan and Potparević, Biljana",
year = "2014",
abstract = "It is well recognized that cancers develop and grow as a result of disordered function of tumor suppressor genes and oncogenes, which may be exploited for screening purposes. Extensive evidence indicated tumor suppressor protein p53 as candidate marker for mutation identification. We have investigated mutant p53 protein expression in human breast tumors in relation to antioxidant status deficiency. The study included 100 breast cancer patients. p53 protein expression was evaluated by Western blot assay and immunostaining using a CM-1, DO-7 and Pab240 antibodies. Antioxidant parameters and lipid peroxidation were estimated by biochemical analyses. Western blotting with epitope-specific monoclonal antibody Pab240 strongly suggests that nuclear extracts from breast cancer cells express mutant forms of p53. It is of interest that the mutant forms of p53 overexpression in conjunction with the appearance of nuclear bodies are observed in highly aggressive carcinomas. Expression of isoform Delta p53 (45 kDa) and isoform of similar to 29 kDa were more common in cases with LN metastasis. These studies point out the molecular consequences of oxidative stress (lipid peroxides, LP, p lt 0.001) and antioxidant status deficiency (copper, zinc superoxid dismutase, SOD, p lt 0.001; catalase, CAT, p lt 0.01; glutathione reductase, GR, p lt 0.001; glutathione, GSH, p lt 0.05) and indicate the importance of p53 mutation as the commonest genetic alteration detected in breast cancer cells. The expression of mutant p53 is correlated to increased lipid peroxides (0.346, p lt 0.05) and lowered antioxidant activity of CAT (- 0.437, p lt 0.01) in the breast cancer patients.",
publisher = "Excli Journal Managing Office, Dortmund",
journal = "EXCLI Journal",
title = "Mutant p53 protein expression and antioxidant status deficiency in breast cancer",
volume = "13",
pages = "691-708",
url = "https://hdl.handle.net/21.15107/rcub_vinar_113"
}

Milicević, Z., Kasapović, J., Gavrilović, L., Milovanović, Z., Bajić, V.,& Potparević, B.. (2014). Mutant p53 protein expression and antioxidant status deficiency in breast cancer. in EXCLI Journal
Excli Journal Managing Office, Dortmund., 13, 691-708.
https://hdl.handle.net/21.15107/rcub_vinar_113

Milicević Z, Kasapović J, Gavrilović L, Milovanović Z, Bajić V, Potparević B. Mutant p53 protein expression and antioxidant status deficiency in breast cancer. in EXCLI Journal. 2014;13:691-708.
https://hdl.handle.net/21.15107/rcub_vinar_113 .

Milicević, Zorka, Kasapović, Jelena, Gavrilović, Ljubica, Milovanović, Zorka, Bajić, Vladan, Potparević, Biljana, "Mutant p53 protein expression and antioxidant status deficiency in breast cancer" in EXCLI Journal, 13 (2014):691-708,
https://hdl.handle.net/21.15107/rcub_vinar_113 .